

Meet the Network and Community Leadership Network: Translational & Precision Medicine (TPM)



Network Past Chair:
Michelle A. Rudek,
PharmD, PhD
Johns Hopkins University

Dr. Michelle A. Rudek, PharmD, PhD, is an Associate Professor of Oncology at Johns Hopkins University (JHU) School of Medicine. Dr. Rudek received her dual PharmD, PhD from Virginia Commonwealth University (VCU) in a joint program with the National Cancer Institute (NCI). After completing a PharmD, PhD, Dr. Rudek joined JHU and became incorporated into the Drug Development Program. Her research program is focused on clinical pharmacology with a focus on oncology (Phase I clinical trials/early phase drug development) and special populations (AIDS malignancy and organ dysfunction). Currently, Dr. Rudek is the Director of the Analytical Pharmacology Core Laboratory and Co-Leader of the Drug Analysis Unit of the JHU Institute for Clinical and Translational Research (ICTR). She is a co-PI of the Johns Hopkins Translational Science Team for the NCI - Experimental Therapeutics Clinical Trials Network and co-investigator on numerous grants from NIH and private funding. Dr. Rudek is the Subject Matter Expert in Pharmacology of the NCI's Investigational Drug Steering Committee (IDSC), Chair of the NCI's IDSC Pharmacology Task Force, Co-chair of the NCI's Organ Dysfunction Working Group (ODWG), Co-chair of the AIDS Malignancy Clinical (AMC) Trials Consortium Translational Science Working Group, and Member of the Adult Brain Tumor Consortium (ABTC) Pharmacology Committee. She has authored over 110 scientific papers in peer reviewed journals focused on the clinical pharmacology of anti-cancer drug. Dr. Rudek is an active member of the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and American Society of Clinical Pharmacology and Therapeutics (ASCPT), and serves on the editorial board of several journals.